Peringatan Keamanan

Single oral doses of ticlopidine at 1600 mg/kg and 500 mg/kg were lethal to rats and mice, respectively. Symptoms of acute toxicity were GI hemorrhage, convulsions, hypothermia, dyspnea, loss of equilibrium and abnormal gait. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine.

Ticlopidine

DB00208

small molecule approved

Deskripsi

Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine.

Struktur Molekul 2D

Berat 263.786
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Half-life following a single 250-mg dose is approximately 7.9 hours in subjects 20 to 43 years of age and 12.6 hours in subjects 65 to 76 years of age. With repeated dosing (250 mg twice a day), half-life is about 4 days in subjects 20 to 43 years of age and about 5 days in subjects 65 to 76 years of age.
Volume Distribusi The volume of distribution was not quantified.
Klirens (Clearance) Ticlopidine clearance was not quantified, but clearance decreases with age.

Absorpsi

Absorption is greater than 80%. Food increases absorption by approximately 20%.

Metabolisme

Ticlopidine is metabolized extensively by the liver with only trace amounts of intact drug detected. At least 20 metabolites have been identified.

Rute Eliminasi

Ticlopidine is eliminated mostly in the urine (60%) and somewhat in the feces (23%).

Interaksi Makanan

2 Data
  • 1. Take with a high fat meal. High fat meals will increase ticlopidine absorption.
  • 2. Take with food. Food can help ticlopidine-induced stomach upset.

Interaksi Obat

1463 Data
Apixaban The risk or severity of adverse effects can be increased when Ticlopidine is combined with Apixaban.
Dasatinib Dasatinib may increase the anticoagulant activities of Ticlopidine.
Ursodeoxycholic acid The risk or severity of adverse effects can be increased when Ticlopidine is combined with Ursodeoxycholic acid.
Glycochenodeoxycholic Acid The risk or severity of adverse effects can be increased when Ticlopidine is combined with Glycochenodeoxycholic Acid.
Cholic Acid The risk or severity of adverse effects can be increased when Ticlopidine is combined with Cholic Acid.
Glycocholic acid The risk or severity of adverse effects can be increased when Ticlopidine is combined with Glycocholic acid.
Deoxycholic acid The risk or severity of adverse effects can be increased when Ticlopidine is combined with Deoxycholic acid.
Taurocholic acid The risk or severity of adverse effects can be increased when Ticlopidine is combined with Taurocholic acid.
Obeticholic acid The risk or severity of adverse effects can be increased when Ticlopidine is combined with Obeticholic acid.
Chenodeoxycholic acid The risk or severity of adverse effects can be increased when Ticlopidine is combined with Chenodeoxycholic acid.
Taurochenodeoxycholic acid The risk or severity of adverse effects can be increased when Ticlopidine is combined with Taurochenodeoxycholic acid.
Tauroursodeoxycholic acid The risk or severity of adverse effects can be increased when Ticlopidine is combined with Tauroursodeoxycholic acid.
Bamet-UD2 The risk or severity of adverse effects can be increased when Ticlopidine is combined with Bamet-UD2.
Dehydrocholic acid The risk or severity of adverse effects can be increased when Ticlopidine is combined with Dehydrocholic acid.
Hyodeoxycholic Acid The risk or severity of adverse effects can be increased when Ticlopidine is combined with Hyodeoxycholic Acid.
Glucosamine Glucosamine may increase the antiplatelet activities of Ticlopidine.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ticlopidine is combined with Ibritumomab tiuxetan.
Ibrutinib The risk or severity of adverse effects can be increased when Ibrutinib is combined with Ticlopidine.
Obinutuzumab The risk or severity of adverse effects can be increased when Ticlopidine is combined with Obinutuzumab.
Pentoxifylline Pentoxifylline may increase the antiplatelet activities of Ticlopidine.
Rivaroxaban Ticlopidine may increase the anticoagulant activities of Rivaroxaban.
Tipranavir Tipranavir may increase the antiplatelet activities of Ticlopidine.
Urokinase Ticlopidine may increase the anticoagulant activities of Urokinase.
Vitamin E Vitamin E may increase the antiplatelet activities of Ticlopidine.
Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Ticlopidine.
Citalopram The serum concentration of Citalopram can be increased when it is combined with Ticlopidine.
Flibanserin The serum concentration of Flibanserin can be increased when it is combined with Ticlopidine.
Clopidogrel The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Ticlopidine resulting in a loss in efficacy.
Dabrafenib The serum concentration of Ticlopidine can be decreased when it is combined with Dabrafenib.
Luliconazole The serum concentration of Ticlopidine can be increased when it is combined with Luliconazole.
Caffeine The metabolism of Caffeine can be decreased when combined with Ticlopidine.
Theophylline The metabolism of Theophylline can be decreased when combined with Ticlopidine.
Dyphylline The metabolism of Dyphylline can be decreased when combined with Ticlopidine.
Mercaptopurine The metabolism of Mercaptopurine can be decreased when combined with Ticlopidine.
Aminophylline The metabolism of Aminophylline can be decreased when combined with Ticlopidine.
Oxtriphylline The metabolism of Oxtriphylline can be decreased when combined with Ticlopidine.
Theobromine The metabolism of Theobromine can be decreased when combined with Ticlopidine.
Fenethylline The metabolism of Fenethylline can be decreased when combined with Ticlopidine.
8-azaguanine The metabolism of 8-azaguanine can be decreased when combined with Ticlopidine.
7,9-Dimethylguanine The metabolism of 7,9-Dimethylguanine can be decreased when combined with Ticlopidine.
Xanthine The metabolism of Xanthine can be decreased when combined with Ticlopidine.
7-Deazaguanine The metabolism of 7-Deazaguanine can be decreased when combined with Ticlopidine.
Guanine The metabolism of Guanine can be decreased when combined with Ticlopidine.
9-Methylguanine The metabolism of 9-Methylguanine can be decreased when combined with Ticlopidine.
Peldesine The metabolism of Peldesine can be decreased when combined with Ticlopidine.
Hypoxanthine The metabolism of Hypoxanthine can be decreased when combined with Ticlopidine.
9-Deazaguanine The metabolism of 9-Deazaguanine can be decreased when combined with Ticlopidine.
Propentofylline The metabolism of Propentofylline can be decreased when combined with Ticlopidine.
Valomaciclovir The metabolism of Valomaciclovir can be decreased when combined with Ticlopidine.
3-isobutyl-1-methyl-7H-xanthine The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Ticlopidine.
Uric acid The metabolism of Uric acid can be decreased when combined with Ticlopidine.
Doxofylline The metabolism of Doxofylline can be decreased when combined with Ticlopidine.
6-O-benzylguanine The metabolism of 6-O-benzylguanine can be decreased when combined with Ticlopidine.
Lisofylline The metabolism of Lisofylline can be decreased when combined with Ticlopidine.
Lobucavir The metabolism of Lobucavir can be decreased when combined with Ticlopidine.
Cafedrine The metabolism of Cafedrine can be decreased when combined with Ticlopidine.
Theodrenaline The metabolism of Theodrenaline can be decreased when combined with Ticlopidine.
Bamifylline The metabolism of Bamifylline can be decreased when combined with Ticlopidine.
Proxyphylline The metabolism of Proxyphylline can be decreased when combined with Ticlopidine.
Acefylline The metabolism of Acefylline can be decreased when combined with Ticlopidine.
Etamiphylline The metabolism of Etamiphylline can be decreased when combined with Ticlopidine.
Pentifylline The metabolism of Pentifylline can be decreased when combined with Ticlopidine.
Bufylline The metabolism of Bufylline can be decreased when combined with Ticlopidine.
Bromotheophylline The metabolism of Bromotheophylline can be decreased when combined with Ticlopidine.
Furafylline The metabolism of Furafylline can be decreased when combined with Ticlopidine.
8-chlorotheophylline The metabolism of 8-chlorotheophylline can be decreased when combined with Ticlopidine.
PCS-499 The metabolism of PCS-499 can be decreased when combined with Ticlopidine.
Zolmitriptan The metabolism of Zolmitriptan can be decreased when combined with Ticlopidine.
Atomoxetine The metabolism of Atomoxetine can be decreased when combined with Ticlopidine.
Mirabegron The serum concentration of Ticlopidine can be increased when it is combined with Mirabegron.
Pentosan polysulfate The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Ticlopidine.
Limaprost Limaprost may increase the antiplatelet activities of Ticlopidine.
Omega-3 fatty acids Omega-3 fatty acids may increase the antiplatelet activities of Ticlopidine.
Tositumomab The risk or severity of adverse effects can be increased when Ticlopidine is combined with Tositumomab.
Lumacaftor The serum concentration of Ticlopidine can be decreased when it is combined with Lumacaftor.
Lepirudin The risk or severity of bleeding can be increased when Ticlopidine is combined with Lepirudin.
Bivalirudin The risk or severity of bleeding can be increased when Ticlopidine is combined with Bivalirudin.
Alteplase The risk or severity of bleeding can be increased when Ticlopidine is combined with Alteplase.
Reteplase The risk or severity of bleeding can be increased when Ticlopidine is combined with Reteplase.
Anistreplase The risk or severity of bleeding can be increased when Ticlopidine is combined with Anistreplase.
Tenecteplase The risk or severity of bleeding can be increased when Ticlopidine is combined with Tenecteplase.
Abciximab The risk or severity of bleeding can be increased when Ticlopidine is combined with Abciximab.
Drotrecogin alfa The risk or severity of bleeding can be increased when Ticlopidine is combined with Drotrecogin alfa.
Streptokinase The risk or severity of bleeding can be increased when Ticlopidine is combined with Streptokinase.
Dicoumarol The risk or severity of bleeding can be increased when Ticlopidine is combined with Dicoumarol.
Argatroban The risk or severity of bleeding can be increased when Ticlopidine is combined with Argatroban.
Ardeparin The risk or severity of bleeding can be increased when Ticlopidine is combined with Ardeparin.
Phenindione The risk or severity of bleeding can be increased when Ticlopidine is combined with Phenindione.
Fondaparinux The risk or severity of bleeding can be increased when Ticlopidine is combined with Fondaparinux.
Warfarin The risk or severity of bleeding can be increased when Ticlopidine is combined with Warfarin.
Phenprocoumon The risk or severity of bleeding can be increased when Ticlopidine is combined with Phenprocoumon.
Dipyridamole The risk or severity of bleeding can be increased when Ticlopidine is combined with Dipyridamole.
Heparin The risk or severity of bleeding can be increased when Ticlopidine is combined with Heparin.
Enoxaparin The risk or severity of bleeding can be increased when Ticlopidine is combined with Enoxaparin.
Epoprostenol The risk or severity of bleeding can be increased when Ticlopidine is combined with Epoprostenol.
Acenocoumarol The risk or severity of bleeding can be increased when Ticlopidine is combined with Acenocoumarol.
4-hydroxycoumarin The risk or severity of bleeding can be increased when Ticlopidine is combined with 4-hydroxycoumarin.
Coumarin The risk or severity of bleeding can be increased when Ticlopidine is combined with Coumarin.
Ximelagatran The risk or severity of bleeding can be increased when Ticlopidine is combined with Ximelagatran.
Desmoteplase The risk or severity of bleeding can be increased when Ticlopidine is combined with Desmoteplase.

Target Protein

Platelet-activating factor receptor PTAFR
P2Y purinoceptor 12 P2RY12

Referensi & Sumber

Contoh Produk & Brand

Produk: 21 • International brands: 0
Produk
  • Alti-ticlopidine - Tab 250mg
    Tablet • 250 mg • Oral • Canada • Generic • Approved
  • Dom-ticlopidine
    Tablet • 250 mg • Oral • Canada • Generic • Approved
  • Mylan-ticlopidine
    Tablet • 250 mg • Oral • Canada • Generic • Approved
  • PMS-ticlopidine
    Tablet • 250 mg • Oral • Canada • Generic • Approved
  • Sandoz Ticlopidine
    Tablet • 250 mg • Oral • Canada • Generic • Approved
  • Teva-ticlopidine
    Tablet • 250 mg • Oral • Canada • Generic • Approved
  • Ticlid
    Tablet, film coated • 250 mg/1 • Oral • US • Approved
  • Ticlid
    Tablet, film coated • 250 mg/1 • Oral • US • Approved
Menampilkan 8 dari 21 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul